Unknown

Dataset Information

0

Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.


ABSTRACT: Naloxone (17-allyl-4,5?-epoxy-3,14-dihydroxymorphinan-6-one HCl), a ?-opioid receptor antagonist, is administered intranasally to reverse an opioid overdose but its short half-life may necessitate subsequent doses. The addition of naltrexone [17-(cyclopropylmethyl)-4,5?-epoxy-3,14-dihydroxymorphinan-6-one], another ?-receptor antagonist, which has a reported half-life of 3 1/2 hours, may extend the available time to receive medical treatment. In a phase 1 pharmacokinetic study, healthy adults were administered naloxone and naltrexone intranasally, separately and in combination. When administered with naloxone, the C max value of naltrexone decreased 62% and the area under the concentration-time curve from time zero to infinity (AUC0-inf) decreased 38% compared with when it was given separately; lower concentrations of naltrexone were observed as early as 5 minutes postdose. In contrast, the C max and AUC0-inf values of naloxone decreased only 18% and 16%, respectively, when given with naltrexone. This apparent interaction was investigated further to determine if naloxone and naltrexone shared a transporter. Neither compound was a substrate for organic cation transporter (OCT) 1, OCT2, OCT3, OCTN1, or OCTN2. There was no evidence of the involvement of a transmembrane transporter when they were tested separately or in combination at concentrations of 10 and 500 µM using Madin-Darby canine kidney II cell monolayers at pH 7.4. The efflux ratios of naloxone and naltrexone increased to six or greater when the apical solution was pH 5.5, the approximate pH of the nasal cavity; there was no apparent interaction when the two were coincubated. The importance of understanding how opioid antagonists are absorbed by the nasal epithelium is magnified by the rise in overdose deaths attributed to long-lived synthetic opioids and the realization that better strategies are needed to treat opioid overdoses.

SUBMITTER: Krieter P 

PROVIDER: S-EPMC6548978 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.

Krieter Philip P   Chiang C Nora CN   Gyaw Shwe S   Skolnick Phil P   Snyder Rebekah R  

Drug metabolism and disposition: the biological fate of chemicals 20190416 7


Naloxone (17-allyl-4,5<i>α</i>-epoxy-3,14-dihydroxymorphinan-6-one HCl), a <i>μ</i>-opioid receptor antagonist, is administered intranasally to reverse an opioid overdose but its short half-life may necessitate subsequent doses. The addition of naltrexone [17-(cyclopropylmethyl)-4,5<i>α</i>-epoxy-3,14-dihydroxymorphinan-6-one], another <i>μ</i>-receptor antagonist, which has a reported half-life of 3 1/2 hours, may extend the available time to receive medical treatment. In a phase 1 pharmacokine  ...[more]

Similar Datasets

| S-EPMC6099239 | biostudies-literature
| S-EPMC7591087 | biostudies-literature
| S-EPMC5723108 | biostudies-literature
| S-EPMC3586101 | biostudies-literature
| S-EPMC6157667 | biostudies-literature
| S-EPMC6606390 | biostudies-literature
| S-EPMC3837847 | biostudies-other
| S-EPMC7167593 | biostudies-literature
| S-EPMC6785104 | biostudies-literature
| S-EPMC5298089 | biostudies-literature